The role of somatostatin analogs in the management of immunoproliferative disease.
Ferone
D
D
Department of Endocrinological and Metabolic Sciences, University of Genova, Italy. ferone@unige.it
Arvigo
M
M
Semino
C
C
Pivonello
R
R
van Hagen
P M
PM
Barreca
A
A
Minuto
F
F
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006801:Humans; D007160:Immunoproliferative Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D008214:Lymphocytes / Q000378:metabolism*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D019275:Radiopharmaceuticals; D051381:Rats; D017481:Receptors, Somatostatin / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014018:Tissue Distribution
D018931:Antineoplastic Agents, Hormonal; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D013004:Somatostatin